Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.56 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | RHEB | Q15382 | 1/20 | 0.56 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.52 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.52 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.49 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 2/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31027982 | 1.00 | HDAC6 (0.59) | HDAC6DGAT1SOAT1KCNH2RHEB | |
| SCHEMBL1842216 | 0.85 | PKN1 (0.59) | DGAT1SOAT1KCNH2RHEBPKN1 | |
| SCHEMBL1842081 | 0.82 | RHEB (0.59) | DGAT1SOAT1KCNH2RHEBPKN1 | |
| SCHEMBL8412123 | 0.82 | RHEB (0.59) | DGAT1SOAT1KCNH2RHEBPKN1 | |
| SCHEMBL19994470 | 0.82 | RHEB (0.59) | DGAT1SOAT1KCNH2RHEBPKN1 | |
| SCHEMBL3333407 | 0.82 | RHEB (0.68) | DGAT1SOAT1KCNH2RHEBPKN1 | |
| SCHEMBL28267390 | 0.81 | CHEK2 (0.61) | DGAT1SOAT1KCNH2RHEBPKN1 | |
| SCHEMBL10765155 | 0.81 | RHEB (0.59) | DGAT1SOAT1KCNH2RHEBPKN1 | |
| SCHEMBL30343743 | 0.81 | RHEB (0.56) | DGAT1SOAT1KCNH2RHEBPKN1 | |
| SCHEMBL20001680 | 0.81 | RHEB (0.56) | DGAT1SOAT1KCNH2RHEBPKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-30 | — | — | US | disclosed |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-03-04 | — | — | US | disclosed |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020033359-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 101/4885DGAT1 497/4885SOAT1 2048/4885 |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 91/4885DGAT1 800/4885SOAT1 2641/4885 |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 107/4885DGAT1 386/4885SOAT1 1637/4885 |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | HDAC6 107/4885DGAT1 386/4885SOAT1 1637/4885 |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | HDAC6 101/4885DGAT1 497/4885SOAT1 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.